TD Cowen analyst Ritu Baral maintains $Sarepta Therapeutics (SRPT.US)$ with a buy rating, and maintains the target price at $203.
According to TipRanks data, the analyst has a success rate of 49.5% and a total average return of 14.3% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Following Sarepta's announcement of an agreement with Arrowhead to license several clinical and preclinical programs, including a substantial upfront payment and equity investment, optimism around the deal is evident. This arrangement is seen enhancing Sarepta's pipeline, introducing more revenue possibilities beyond its main DMD franchise over the long term. It also aligns with the strategic goal to diversify beyond the initial focus on single-application gene therapies, addressing some investor concerns around the need for broader diversification.
The agreement with Arrowhead provides a diversified platform with a clear focus on long-term investment in strategies for rare chronic diseases and expands the therapeutic range to include muscle, central nervous system, and pulmonary indications. The alliance is strategically apt given Sarepta's expertise in rare genetic medicine, and the initiation of a share buyback program indicates a positive outlook on near-term revenue prospects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
TD Cowen分析師Ritu Baral維持$Sarepta Therapeutics (SRPT.US)$買入評級，維持目標價203美元。
根據TipRanks數據顯示，該分析師近一年總勝率為49.5%，總平均回報率為14.3%。
此外，綜合報道，$Sarepta Therapeutics (SRPT.US)$近期主要分析師觀點如下：
在Sarepta宣佈與Arrowhead達成協議授權多項臨床和臨床前項目，包括大額前期付款和股權投資之後，市場對該交易充滿樂觀。這一安排被認爲將增強Sarepta的項目管線，在長期內引入更多營業收入可能，超越其主要的DMD特許經銷權。這也符合戰略目標，超越最初關注單一應用基因療法，解決了一些投資者對於需要更廣泛多元化的擔憂。
與Arrowhead的協議提供了一個多元化平台，明確專注於對罕見慢性疾病的長期投資策略，並將治療範圍擴大到包括肌肉、中樞神經系統和肺部指標。考慮到Sarepta在罕見基因醫學方面的專業知識，以及啓動股票回購計劃顯示出對近期營收前景的樂觀態度，這一聯盟在戰略上是恰當的。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
